Sequence: CYGRKKRRQRRR
| Experiment Id | EXP002052 |
|---|---|
| Paper | TAT Peptides Mediated Small Interfering RNA Delivery to Huh-7 Cells and Efficiently Inhibited Hepati |
| Peptide | HIV-1 TAT 47–57 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | 0.5–1.5 µg conjugate (added to culture medium) |
| Rna Concentration | 0.5–1.5 µg conjugate (added to culture medium) |
| Mixing Ratio | 1:1 molar (activated siRNA:TAT peptide during conjugation) |
| Formulation Format | covalent peptide–siRNA conjugate |
| Formulation Components | TAT47–57 peptide (N-term Cys) + anti-HCV siRNA; sulfo-SMPB crosslinker; DY547 label (for uptake) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | Huh-7 (human hepatoma) with HCV luciferase replicon reporter |
| Animal Model | |
| Administration Route | Incubation in cell culture (conjugate added to medium) |
| Output Type | HCV replicon inhibition (luciferase) and HCV RNA reduction (RT-qPCR) |
| Output Value | Up to 96.5% luciferase inhibition (1.5 µg conjugate); HCV RNA decreased dose-dependently |
| Output Units | |
| Output Notes | siRNA–TAT conjugate showed uptake comparable to Lipofectamine-siRNA; unconjugated siRNA + free TAT showed no effect; 1.0 µg siRNA–TAT ~ Lipofectamine-siRNA effect. |
| Toxicity Notes | ~85% cell viability by trypan blue; less toxic than Lipofectamine 2000 |
| Curation Notes |